Frequency of newly acquired N-glycosylation sites (NANGS) in t(14;18)-positive and t(14;18)-negative treatment-naive and relapsed FL stage I/II and stage III/IV
| Clinical stage . | t(14;18)-positive* . | t(14;18)-negative* . | P . |
|---|---|---|---|
| NANGS frequency | |||
| FL I/II | 10/14 (∼71.4%) | 10/14 (∼71.4%) | NS |
| FL III/IV | 10/16 (62.5%) | 2/10 (20%) | .042† |
| P | .71 | .036 | |
| Clinical stage . | t(14;18)-positive* . | t(14;18)-negative* . | P . |
|---|---|---|---|
| NANGS frequency | |||
| FL I/II | 10/14 (∼71.4%) | 10/14 (∼71.4%) | NS |
| FL III/IV | 10/16 (62.5%) | 2/10 (20%) | .042† |
| P | .71 | .036 | |
I/II, early-stage FL; III/IV, advanced-stage FL; NS, not significant.
Includes only treatment-naive and relapsed FL with clinical stage available.
The comparison t(14;18)-positive vs t(14;18)-negative was performed with a one-sided Fisher’s exact test (directed hypothesis due to previous findings18 ).